...
首页> 外文期刊>International Journal of Neuroscience >Methylenetetrahydrofolate reductase C677T polymorphism, hypertension and risk of stroke: a prospective, nested case-control study
【24h】

Methylenetetrahydrofolate reductase C677T polymorphism, hypertension and risk of stroke: a prospective, nested case-control study

机译:亚甲基四氢呋喃还原酶C677T多态性,高血压和中风的风险:前瞻性,嵌套病例对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Hyperhomocysteinemia is a risk factor for cardiovascular disease. To date, limited prospective studies have examined the joint effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, hyperhomocysteinemia and conventional vascular risk factors on risk of stroke and stroke death. Methods: A total of 39165 subjects from nine communities within Anqing, Anhui Province, China were prospectively followed from March 1995 to April 2005, with an average follow-up period of 6.2 years. None of the subjects had any history of vascular events at baseline. At follow-up, 251 incident stroke cases were identified. Using a nested, case-control study design, this analysis includes 106 cases with complete MTHFR C677T genotyping data and plasma samples. We selected 106 controls without vascular events matched for age, sex, community and years of plasma storage. Plasma total homocysteine (tHcy) level was measured by high-performance liquid chromatography. Results: Hypertension was independently associated with incident stroke and stroke death after adjusting for important covariates including plasma log-transformed Hcy level. Relative to non-carriers of the MTHFR 677TT genotype with no hypertension, the adjusted odds ratio (95% confidence interval) of stroke and stroke death among hypertensive carriers of the MTHFR 677TT genotype was 10.6 (3.2 to 34.8), 5.8 (1.6 to 21.3), respectively. After excluding subjects with plasma Hcy above 20 mol/L, the relative odds for stroke, but not for stroke death, was more significantly pronounced (OR = 24.1, 95% CI: 2.3 to 246.1) among subjects with moderate plasma Hcy levels. However, there was no significant interactive effect between hypertensive status and the MTHFR C677T variant on the odds of the two outcomes as estimated by interaction models. Conclusions: Our major findings suggest that joint effects of the MTHFR C677T polymorphism and hypertension are consistent in predicting a significantly high risk of stroke. In addition for moderate plasma levels of Hcy, the predicted effects on the risk for the primary end point of stroke were more pronounced. These results may help to modify current approaches to vascular disease prevention in Chinese hypertensive patients.
机译:背景:Hyperhomysteinemia是心血管疾病的危险因素。迄今为止,有限的前瞻性研究检测了亚甲基四氢溶胶还原酶(MTHFR)C677T多态性,高流管血症和常规血管危险因素对卒中和中风死亡风险的关节作用。方法:中国安徽省安庆市安庆中共有39165名九社区受试者,从1995年3月至2005年4月,平均随访时间为6.2岁。没有一个受试者在基线上有任何血管事件的历史。在随访时,确定了251例事件卒中案件。使用嵌套的案例控制研究设计,该分析包括106例,具有完整的MTHFR C677T基因分型数据和等离子体样品。我们选择了106个控制,没有血管事件,符合年龄,性别,社区和多年等离子体储存。通过高效液相色谱法测量血浆总同型半胱氨酸(THCY)水平。结果:调整包括血浆对数转化的HCY水平的重要协变量后,高血压与事件中风和中风死亡独立相关。相对于没有高血压的MTHFR 677TT基因型的非载体,MTHFR 677TT基因型的高血压载体中风和中风死亡的调整后的大量比(95%置信度)为10.6(3.2至34.8),5.8(1.6〜21.3 ), 分别。在将血浆Hcy以上血浆Hcy以上的受试者排除在20mol / L以上时,中风的相对次数,但不用于中风死亡,在具有中度血浆Hcy水平的受试者中更显着明显(或= 24.1,95%CI:2.3至246.1)。然而,高血压状态和MTHFR C677T变体之间没有显着的交互效果,这是通过交互模型估计的两种结果的几率。结论:我们的主要研究结果表明MTHFR C677T多态性和高血压的联合效应是一致预测卒中显着高的风险。除了适度的Hcy血浆水平,对卒中主要终点点风险的预测效果更加明显。这些结果可能有助于改变中国高血压患者血管疾病预防的当前方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号